Literature DB >> 16610570

Cutaneous malignant melanoma.

Deborah L Cummins1, Jordan M Cummins, Hardin Pantle, Michael A Silverman, Aimee L Leonard, Arjun Chanmugam.   

Abstract

Skin cancer has become the most common neoplasm in the United States. With early diagnosis and appropriate management, most skin cancers have an overall 5-year survival rate of 95%. Cutaneous malignant melanoma (CMM), however, has a significantly higher morbidity and mortality, resulting in 65% of all skin cancer deaths. Although the long-term survival rate for patients with metastatic melanoma is only 5%, early detection of CMM carries an excellent prognosis, with surgical excision often being curative. Primary care physicians can play a critical role in reducing morbidity and mortality from CMM by recognizing patients at risk, encouraging the adoption of risk-reducing behaviors, and becoming adept at identifying suspicious lesions.

Entities:  

Mesh:

Year:  2006        PMID: 16610570     DOI: 10.4065/81.4.500

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  91 in total

1.  β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.

Authors:  Stanley Lemeshow; Henrik Toft Sørensen; Gary Phillips; Eric V Yang; Sussie Antonsen; Anders H Riis; Gregory B Lesinski; Rebecca Jackson; Ronald Glaser
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-20       Impact factor: 4.254

Review 2.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

3.  Development of tumor-infiltrating CD8+ T cell memory precursor effector cells and antimelanoma memory responses are the result of vaccination and TGF-β blockade during the perioperative period of tumor resection.

Authors:  Emily C Bellavance; Frederick J Kohlhapp; Andrew Zloza; Jeremy A O'Sullivan; James McCracken; Michael C Jagoda; Andrew T Lacek; Mitchell C Posner; Jose A Guevara-Patino
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

Review 4.  Optical-resolution photoacoustic microscopy: auscultation of biological systems at the cellular level.

Authors:  Song Hu; Lihong V Wang
Journal:  Biophys J       Date:  2013-08-20       Impact factor: 4.033

5.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

6.  CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.

Authors:  Kavita V Shah; Andy J Chien; Cassian Yee; Randall T Moon
Journal:  J Invest Dermatol       Date:  2008-06-19       Impact factor: 8.551

7.  Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells.

Authors:  Marina Pisano; Gabriella Pagnan; Maria Antonietta Dettori; Sara Cossu; Irene Caffa; Ilaria Sassu; Laura Emionite; Davide Fabbri; Michele Cilli; Fabio Pastorino; Giuseppe Palmieri; Giovanna Delogu; Mirco Ponzoni; Carla Rozzo
Journal:  Mol Cancer       Date:  2010-06-03       Impact factor: 27.401

8.  Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies.

Authors:  Luca Sigalotti; Alessia Covre; Elisabetta Fratta; Giulia Parisi; Francesca Colizzi; Aurora Rizzo; Riccardo Danielli; Hugues J M Nicolay; Sandra Coral; Michele Maio
Journal:  J Transl Med       Date:  2010-06-11       Impact factor: 5.531

Review 9.  Why target the tumor stroma in melanoma?

Authors:  James Hutchenreuther; Andrew Leask
Journal:  J Cell Commun Signal       Date:  2017-11-06       Impact factor: 5.782

10.  Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide cytotoxicity via a reactive oxygen species dependent mechanism.

Authors:  Benjamin D Bowling; Nicole Doudican; Prashiela Manga; Seth J Orlow
Journal:  Cancer Chemother Pharmacol       Date:  2008-02-23       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.